Editor's Corner

More grist for PCSK9 fight as Amgen sets up EU to pay about half as much as U.S.

Last week, Amgen won its much-anticipated FDA approval for the PCSK9 cholesterol-fighter Repatha and promptly set a price of $14,100 per year. But even after pharmacy benefits managers and insurers wring out their discounts, the cost is unlikely to be nearly as low as Repatha's price tag in Europe.

Report: Real-world Blincyto spending likely to fall far short of Amgen's $178K list price

When Amgen rolled out its Blincyto treatment for an ultra-rare form of leukemia, the California biotech set what seemed to be an eye-watering price--$178,000 for a typical patient. But some number-crunching of clinical trial data, coupled with documents from the Centers for Medicare and Medicaid Services, suggests that the real-world cost will be much lower.

European pharma lobby says 'non' to French funding for off-label Avastin

The French government recently said "oui" to Roche's ($RHHBY) cancer drug Avastin as a cheap, off-label treatment for the blinding eye disease wet age-related macular degeneration (AMD), prompting a resounding "non" from the pharma industry, which is none-too-pleased with the country's latest move.

Valeant doubles size of its HQ as deal spree continues

Serial buyer Valeant is expanding quickly, and to keep up, it's expanding its office space, too. The Canadian pharma has leased another 310,000 square feet at Somerset Corporate Center in Bridgewater, NJ, doubling its footprint at the complex less than two years after setting up its U.S. headquarters there, NJBIZ reports.

Boehringer touts Pradaxa antidote data as FDA decision nears

LONDON--Boehringer Ingelheim's Pradaxa currently trails Johnson & Johnson and Bayer med Xarelto in the market for new-age anticoagulants, but the German drugmaker is hoping a nod for its antidote candidate will help turn the tide in its favor.


From Our Sister Sites


Sage Therapeutics is pressing forward in in the field of tremor treatment after its lead drug notched a positive--though not statistically significant--effect on the debilitating condition in Phase II, results the company believes will help light the way for a bigger trial.


Cell therapy specialist Celyad is set to add Hong Kong to the clinical trial program of its ischemic heart failure treatment, giving its newly recruited partner Medisun data to support an attempt to crack the potentially lucrative Chinese market.